COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort.

ABSTRACT:

Objective

To examine differences in mortality and/or severe acute respiratory syndrome between selective serotonin reuptake inhibitor- (SSRI) users and non-SSRI-users up to 60 days after a positive severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) real-time reverse transcription-polymerase chain reaction (PCR) test.

Methods

Retrospective cohort study including all Danish residents above the age of eighteen with a positive SARS- CoV-2 PCR test from February 26^th, 2020, to October 5^th2021. The follow-up period was 60 days. The primary outcome was all-cause mortality, and the secondary outcome was severe acute respiratory syndrome. Exposure of interest was SSRI-use. Differences between SSRI- users and non-users were examined with Cox Regression.

SUBMITTER: Stauning MA 

PROVIDER: S-EPMC10162844 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature